{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:35:07Z","timestamp":1783442107572,"version":"3.54.6"},"reference-count":43,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2024.0223","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T15:48:23Z","timestamp":1736264903000},"source":"Crossref","is-referenced-by-count":6,"title":["Weaning from tobacco with nicotine or varenicline in severe and mild tobacco dependence\u2014findings of a meta-analysis"],"prefix":"10.3238","author":[{"given":"Claudia","family":"Selbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Siebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jona","family":"Lilienthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Grouven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Knelangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Kastaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Kranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"10.3238\/arztebl.m2024.0223_ref1","unstructured":"Schaller K, Kahnert S, Grean L, Mons U, Ouedraogo N: Tabakatlas Deutschland 2020. www.dkfz.de\/de\/tabakkontrolle\/download\/Publikationen\/sonstVeroeffentlichungen\/Tabakatlas-Deutschland-2020.pdf (last accessed on 5 April 2024)."},{"key":"10.3238\/arztebl.m2024.0223_ref2","unstructured":"Kotz D: DEBRA; Deutsche Befragung zum Rauchverhalten. www.debra-study.info\/ (last accessed on 29 February 2024)."},{"key":"10.3238\/arztebl.m2024.0223_ref3","doi-asserted-by":"crossref","unstructured":"Fagerstrom K: Determinants of tobacco use and renaming the FTND to the fagerstrom test for cigarette dependence. Nicotine Tob Res 2012; 14: 75\u20138","DOI":"10.1093\/ntr\/ntr137"},{"key":"10.3238\/arztebl.m2024.0223_ref4","doi-asserted-by":"crossref","unstructured":"Belluzzi JD, Wang R, Leslie FM: Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 2005; 30: 705\u201312","DOI":"10.1038\/sj.npp.1300586"},{"key":"10.3238\/arztebl.m2024.0223_ref5","unstructured":"AWMF: S3-Leitlinie \u201eRauchen und Tabakabh\u00e4ngigkeit: Screening, Diagnostik und Behandlung\u201d. www.awmf.org\/uploads\/tx_szleitlinien\/076-006l_S3_Rauchen-_Tabakabhaengigkeit-Screening-Diagnostik-Behandlung_2021-03.pdf (last accessed on 29 February 2024)."},{"key":"10.3238\/arztebl.m2024.0223_ref6","doi-asserted-by":"crossref","unstructured":"Fanshawe TR, Halliwell W, Lindson N, Aveyard P, Livingstone-Banks J, Hartmann-Boyce J: Tobacco cessation interventions for young people. Cochrane Database Syst Rev 2017; 11: CD003289","DOI":"10.1002\/14651858.CD003289.pub6"},{"key":"10.3238\/arztebl.m2024.0223_ref7","doi-asserted-by":"crossref","unstructured":"Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T: Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018; 5: CD000146","DOI":"10.1002\/14651858.CD000146.pub5"},{"key":"10.3238\/arztebl.m2024.0223_ref8","doi-asserted-by":"crossref","unstructured":"Claire R, Chamberlain C, Davey MA, et al.: Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2020; 3: CD010078","DOI":"10.1002\/14651858.CD010078.pub3"},{"key":"10.3238\/arztebl.m2024.0223_ref9","doi-asserted-by":"crossref","unstructured":"Thomas KH, Dalili MN, Lopez-Lopez JA, et al.: Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess 2021; 25: 1\u2013224","DOI":"10.3310\/hta25590"},{"key":"10.3238\/arztebl.m2024.0223_ref10","doi-asserted-by":"crossref","unstructured":"Hajizadeh A, Howes S, Theodoulou A, et al.: Antidepressants for smoking cessation. Cochrane Database Syst Rev 2023; 5: CD000031","DOI":"10.1002\/14651858.CD000031.pub6"},{"key":"10.3238\/arztebl.m2024.0223_ref11","doi-asserted-by":"crossref","unstructured":"Livingstone-Banks J, Fanshawe TR, Thomas KH, et al.: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2023; 5: CD006103","DOI":"10.1002\/14651858.CD006103.pub8"},{"key":"10.3238\/arztebl.m2024.0223_ref12","unstructured":"Sozialgesetzbuch (SGB) F\u00fcnftes Buch (V) \u2013 Gesetzliche Krankenversicherung \u2013 (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGBl. I S. 2477). www.gesetze-im-internet.de\/sgb_5\/SGB_5.pdf (last accessed on 28 February 2024)."},{"key":"10.3238\/arztebl.m2024.0223_ref13","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen: Nutzenbewertung von Bupropion, Cytisin, Nicotin und Vareniclin zur Tabakentw\u00f6hnung bei schwerer Tabakabh\u00e4ngigkeit; Abschlussbericht. https:\/\/doi.org\/10.60584\/A22\u201334 (last accessed on 22 January 2024)."},{"key":"10.3238\/arztebl.m2024.0223_ref14","doi-asserted-by":"crossref","unstructured":"Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO: The fagerstrom test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire. Br J Addict 1991; 86: 1119\u201327","DOI":"10.1111\/j.1360-0443.1991.tb01879.x"},{"key":"10.3238\/arztebl.m2024.0223_ref15","unstructured":"Institute for Quality and Efficiency in Health Care: General methods. Version 6.1. www.iqwig.de\/methoden\/general-methods_version-6-1.pdf (last accessed on 11 July 2023)."},{"key":"10.3238\/arztebl.m2024.0223_ref16","doi-asserted-by":"crossref","unstructured":"West R, Hajek P, Stead L, Stapleton J: Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction (Abingdon, England) 2005; 100: 299\u2013303","DOI":"10.1111\/j.1360-0443.2004.00995.x"},{"key":"10.3238\/arztebl.m2024.0223_ref17","unstructured":"Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F: Methods for meta-analysis in medical research. Chichester: Wiley; 2000."},{"key":"10.3238\/arztebl.m2024.0223_ref18","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, et al.: Recommendations for quantifying the uncertainty in the summary intervention effect and estimating the between-study heterogeneity variance in random-effects meta-analysis. Cochrane Database Syst Rev 2015: 25\u20137."},{"key":"10.3238\/arztebl.m2024.0223_ref19","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen: Nutzenbewertung von Bupropion, Cytisin, Nicotin und Vareniclin zur Tabakentw\u00f6hnung bei schwerer Tabakabh\u00e4ngigkeit; Dokumentation der Anh\u00f6rung zum Vorbericht. www.iqwig.de\/download\/a22-34_tabakentwoehnung-bei-schwerer-tabakabhaengigkeit_da-vorbericht_v1-0.pdf (last accessed on 22 January 2024)."},{"key":"10.3238\/arztebl.m2024.0223_ref20","doi-asserted-by":"crossref","unstructured":"Oncken C, Gonzales D, Nides M, et al.: Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166: 1571\u20137","DOI":"10.1001\/archinte.166.15.1571"},{"key":"10.3238\/arztebl.m2024.0223_ref21","doi-asserted-by":"crossref","unstructured":"Gonzales D, Rennard SI, Nides M, et al.: Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. Jama 2006; 296: 47\u201355","DOI":"10.1001\/jama.296.1.47"},{"key":"10.3238\/arztebl.m2024.0223_ref22","doi-asserted-by":"crossref","unstructured":"Jorenby DE, Hays JT, Rigotti NA, et al.: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Jama 2006; 296: 56\u201363","DOI":"10.1001\/jama.296.1.56"},{"key":"10.3238\/arztebl.m2024.0223_ref23","doi-asserted-by":"crossref","unstructured":"Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC: A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007; 29: 1027\u201339","DOI":"10.1016\/j.clinthera.2007.06.011"},{"key":"10.3238\/arztebl.m2024.0223_ref24","doi-asserted-by":"crossref","unstructured":"Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S: Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121: 221\u20139","DOI":"10.1161\/CIRCULATIONAHA.109.869008"},{"key":"10.3238\/arztebl.m2024.0223_ref25","doi-asserted-by":"crossref","unstructured":"Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC: Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139: 591\u20139","DOI":"10.1378\/chest.10-0865"},{"key":"10.3238\/arztebl.m2024.0223_ref26","doi-asserted-by":"crossref","unstructured":"Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S: Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009; 14: 384\u201392","DOI":"10.1111\/j.1440-1843.2008.01476.x"},{"key":"10.3238\/arztebl.m2024.0223_ref27","doi-asserted-by":"crossref","unstructured":"Bolliger CT, Issa JS, Posadas-Valay R, et al.: Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. Clin Ther 2011; 33: 465\u201377","DOI":"10.1016\/j.clinthera.2011.04.013"},{"key":"10.3238\/arztebl.m2024.0223_ref28","doi-asserted-by":"crossref","unstructured":"Rennard S, Hughes J, Cinciripini PM, et al.: A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res 2012; 14: 343\u201350","DOI":"10.1093\/ntr\/ntr220"},{"key":"10.3238\/arztebl.m2024.0223_ref29","doi-asserted-by":"crossref","unstructured":"Anthenelli RM, Morris C, Ramey TS, et al.: Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med 2013; 159: 390\u2013400","DOI":"10.7326\/0003-4819-159-6-201309170-00005"},{"key":"10.3238\/arztebl.m2024.0223_ref30","doi-asserted-by":"crossref","unstructured":"Anthenelli RM, Benowitz NL, West R, et al.: Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387: 2507\u201320","DOI":"10.1016\/S0140-6736(16)30272-0"},{"key":"10.3238\/arztebl.m2024.0223_ref31","doi-asserted-by":"crossref","unstructured":"Gonzales D, Hajek P, Pliamm L, et al.: Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. Clin Pharmacol Ther 2014; 96: 390\u20136","DOI":"10.1038\/clpt.2014.124"},{"key":"10.3238\/arztebl.m2024.0223_ref32","doi-asserted-by":"crossref","unstructured":"Batra A, Klingler K, Landfeldt B, Friederich HM, Westin A, Danielsson T: Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. Clin Pharmacol Ther 2005; 78: 689\u201396","DOI":"10.1016\/j.clpt.2005.08.019"},{"key":"10.3238\/arztebl.m2024.0223_ref33","doi-asserted-by":"crossref","unstructured":"Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P: Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction (Abingdon, England) 2003; 98: 1395\u2013402","DOI":"10.1046\/j.1360-0443.2003.00489.x"},{"key":"10.3238\/arztebl.m2024.0223_ref34","unstructured":"McNeil AB: Efficacy and safety following use of a novel nicotine replacement therapy. www.ClinicalTrials.gov\/show\/NCT00882375 (last accessed on 5 June 2023)."},{"key":"10.3238\/arztebl.m2024.0223_ref35","unstructured":"Nides M, Danielsson T, Saunders F, et al.: Efficacy and safety of a nicotine mouth spray for smoking cessation: a randomized, multicenter, controlled study in a naturalistic setting. Nicotine Tob Res 2020; 22: 339\u201345."},{"key":"10.3238\/arztebl.m2024.0223_ref36","doi-asserted-by":"crossref","unstructured":"Tonnesen P, Norregaard J, Simonsen K, Sawe U: A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 1991; 325: 311\u20135","DOI":"10.1056\/NEJM199108013250503"},{"key":"10.3238\/arztebl.m2024.0223_ref37","doi-asserted-by":"crossref","unstructured":"Sachs DP, Sawe U, Leischow SJ: Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med 1993; 153: 1881\u201390","DOI":"10.1001\/archinte.153.16.1881"},{"key":"10.3238\/arztebl.m2024.0223_ref38","doi-asserted-by":"crossref","unstructured":"Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F: A double-blind trial of a nicotine inhaler for smoking cessation. Jama 1993; 269: 1268\u201371","DOI":"10.1001\/jama.269.10.1268"},{"key":"10.3238\/arztebl.m2024.0223_ref39","doi-asserted-by":"crossref","unstructured":"Hjalmarson A, Nilsson F, Sjostrom L, Wiklund O: The nicotine inhaler in smoking cessation. Arch Intern Med 1997; 157: 1721\u20138","DOI":"10.1001\/archinte.157.15.1721"},{"key":"10.3238\/arztebl.m2024.0223_ref40","unstructured":"Leischow SJ, Nilsson F, Franzon M, Hill A, Otte P, Merikle EP: Efficacy of the nicotine inhaler as an adjunct to smoking cessation. Am J Health Behav 1996; 20: 364\u201371."},{"key":"10.3238\/arztebl.m2024.0223_ref41","doi-asserted-by":"crossref","unstructured":"Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K: Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction (Abingdon, England) 1996; 91: 1293\u2013306","DOI":"10.1111\/j.1360-0443.1996.tb03616.x"},{"key":"10.3238\/arztebl.m2024.0223_ref42","doi-asserted-by":"crossref","unstructured":"Tonnesen P, Paoletti P, Gustavsson G, et al.: Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999; 13: 238\u201346","DOI":"10.1034\/j.1399-3003.1999.13b04.x"},{"key":"10.3238\/arztebl.m2024.0223_ref43","doi-asserted-by":"crossref","unstructured":"Xiao D, Kotler M, Kang J, Wang C: A multicenter, randomized, double-blind, parallel, placebo-controlled clinical study to evaluate the efficacy and safety of a nicotine mint lozenge (2 and 4 mg) in smoking cessation. J Addict Med 2020; 14: 69\u201377","DOI":"10.1097\/ADM.0000000000000547"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T15:49:14Z","timestamp":1736264954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":43,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2024.0223","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]}}}